The impact of implementing the BinaxNow malaria test was evaluated. From 288 tests, 34 malaria cases were detected. Laboratory turnaround time decreased from 9.8 to 1.7 h for report of any Plasmodium spp., 10.2 to 1.6 h for P. falciparum, and 8.6 to 1.1 h for any result.
All technologists performed RDT, but only microbiology technologists prepared and read blood smears.
A total of 288 specimens (67 pre-RDT, 221 post-RDT) qualified for analysis. There were 34 confirmed cases of malaria with positive RDT and blood smears. Blood smears were positive in nine of the 67 patients tested pre-RDT (seven P. falciparum, one P. vivax, one P. ovale). After introduction of RDT, 27 of the 221 patients tested were RDT positive. Blood smears yielded 19 cases of P. falciparum malaria, three P. vivax cases, two P. ovale cases, and one mixed case with P. falciparum and P. ovale. Of the 27 P. falciparum cases with parasites seen on blood smears, 16 had Ͻ1% parasitemia. The remaining 11 cases had 1.2, 2.2, 6.1, 6.3, 6.5, 6.9, 10.1, 15.0, 17.0, 20.4, and 35% parasitemia. In two cases, RDT tested positive for P. falciparum but no parasites were seen on blood smears. Both cases presented febrile and defervesced with atovaquone-proguanil therapy. Neither had an alternative diagnosis to explain the fever. One case arrived in the United States from a refugee camp in Thailand 3 months prior to presentation. Two subsequent sets of thick and thin smears showed no evidence of Plasmodium species. The second case had a travel history to Nigeria 3 weeks prior to presentation during which she reportedly took malaria prophylaxis. Compliance was not documented. A subsequent blood smear was negative for Plasmodium spp. Both cases were analyzed as false positives.
Nine cases with P. falciparum malaria met CDC criteria for severe malaria, and all had parasitemia levels of Ͼ5%. Five cases met other criteria for severe malaria (hypotension, hemoglobin levels of Ͻ7g/dl).
Using Giemsa smears as the gold standard, the sensitivity (SN), specificity (AP), positive predictive value (PPV), and negative predictive value (NPV) of RDT were 100%, 99%, 92%, and 100%, respectively, for the detection of any Plasmodium spp. and 100%, 99%, 91%, and 100% for P. falciparum. RDT detected 5/5 cases of P. vivax and P. ovale. The mixed infection with P. falciparum and P. ovale was analyzed as P. falciparum malaria.
Univariate and multivariate analysis results comparing TAT pre-RDT and post-RDT are summarized in Table 1 . Mean TAT to an actionable malaria report (P. falciparum or non-falciparum malaria) was shorter post-RDT than pre-RDT (1.7 h versus 9.8 h; P Ͻ 0.001), as was mean TAT to a report of P. falciparum malaria (1.6 h versus 10.2 h; P Ͻ 0.001) and mean TAT to any result, positive or negative (1.1 h versus 8.6 h; P Ͻ 0.001). Using multivariate linear regression modeling, overall TAT in specimens received in the post-RDT era remained significantly shorter than that in specimens received pre-RDT after adjusting for shift and staffing (P Ͻ 0.001).
We detected 34 cases of malaria over 6 years in a tertiary, pediatric center where malaria was not endemic. Nine cases met CDC criteria for severe malaria. These findings affirmed the value of allocating resources to support continuous, "24/7" malaria testing at our institution.
The propensity of RDT toward false at parasite loads of Ͻ1,000 parasites/l (or 0.2% parasitemia) is documented in the literature (3). This limitation is important, as nonimmune individuals can be symptomatic at parasitemia levels in this range. Children living in the United States who travel to areas of malaria endemicity without prophylaxis fall in this group. In our cohort, RDT detected all 34 cases of malaria with a sensitivity of 100%, which is consistent with RDT performance data in the literature (3-7). Because we did not retain records of exact parasitemia levels below 1%, we were unable to assess the lower limit of detection of RDT in our population. We therefore counsel clinicians to ensure that additional specimens be collected following a negative result when malaria is strongly suspected. There were two cases in which HRP-2 was positive on RDT but blood smears were negative for parasites. Both cases had a travel history to an area of malaria endemicity and responded clinically to antimalarial therapy. Molecular diagnostics were not pursued to adjudicate the findings as false-positive RDT results or falsenegative blood smears. These cases highlighted the utility of molecular diagnostics, when available, to resolve discordance between RDT and microscopy. We did not observe any cases of P. falciparum malaria misidentified by RDT as non-falciparum malaria as reported by DiMaio et al. (8) .
Introduction of RDT decreased mean TAT from 9.8 to 1.7 h for any positive malaria result, from 10.2 to 1.6 h for a positive P. falciparum result, and from 8.6 to 1.1 h for all results. The TATs were unusually long pre-RDT. We believe that this was related to inconsistent availability of microbiology technologists skilled at preparing Giemsa stain, preparing slides, and reading blood smears. The result was delayed specimen processing. Because all technologists were able to perform RDT, implementation vastly expedited preliminary reporting of all results.
Our study had some limitations. First, because of the small sample size (n ϭ 34 cases), our multivariate analysis was restricted to evaluation of TAT to any result (positive or negative) as opposed to TAT to positive results, the more clinically relevant outcome. Second, technologists reading blood smears were not blinded to RDT results, which may have artificially elevated concordance between RDT and microscopy.
While microscopy remains essential for determination of parasite loads and detection of low-level parasitemia and mixed infections, we conclude that RDT may be useful in settings where malaria is not endemic and that evaluate pediatric patients at risk of P. falciparum malaria. RDT appeared highly sensitive and specific for the detection of P. falciparum malaria in our pediatric population and provided a user-friendly platform that allows reporting of actionable malaria testing results in a "STAT" manner, as recommended by national guidelines (9) . 
